Literature DB >> 12373076

Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury.

Noako Yokota1, Michael O'Donnell, Frank Daniels, Melissa Burne-Taney, William Keane, Bertram Kasiske, Hamid Rabb.   

Abstract

BACKGROUND: Increasing evidence supports an important role for inflammation in the pathogenesis of renal ischemia-reperfusion injury (IRI). Recently, HMG-CoA reductase inhibitors, 'statins', have demonstrated anti-inflammatory effects independent of cholesterol-lowering. HYPOTHESIS: We tested the hypothesis that a statin would improve outcome in a murine model of renal IRI. Upon finding a protective effect, we tested the hypothesis that the mechanisms by which statins protected in renal IRI was by reducing neutrophil and macrophage infiltration and upregulating the anti-inflammatory cytokine IL-6.
METHODS: Cerivastatin at various dosing regimens was administered to NIH Swiss mice to evaluate the effects on renal IRI. Analysis of renal structure, function, neutrophil and macrophage infiltration, cytokine production, as well as mortality was performed in cerivastatin- and saline-treated groups.
RESULTS: PRIMARY: Cerivastatin pretreatment for 3 days led to a significant improvement in renal function, tubular injury as well as survival after IRI compared to saline-treated mice. SECONDARY: Neutrophil and macrophage infiltration into kidney tissue was similar in both groups. IL-6 was markedly upregulated early in the kidneys of statin-treated compared to saline-treated mice.
CONCLUSION: These data demonstrate that a statin compound can improve the course of ischemic acute renal failure. Induction of protective molecules such as IL-6 may underlie this effect. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12373076     DOI: 10.1159/000066301

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  21 in total

Review 1.  Do statins offer therapeutic potential in inflammatory arthritis?

Authors:  I B McInnes; D W McCarey; N Sattar
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

2.  Statins and acute kidney injury following cardiac surgery: has the last word been told?

Authors:  Stefano Romagnoli; Zaccaria Ricci
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

3.  Prevalence and mortality of transient acute kidney injury within 48 h, as new subtype, following coronary angiography: a cohort study.

Authors:  Qiang Li; Mengfei Lin; Haozhang Huang; Liwei Liu; Weihua Chen; Dehua Huang; Ronghui Tang; Miao Zhao; Wen Wei; Bo Wang; Zhidong Huang; Ning Tan; Jiyan Chen; Shiqun Chen; Jin Liu; Yong Liu
Journal:  Clin Exp Nephrol       Date:  2022-01-06       Impact factor: 2.801

4.  Statin administration did not influence the progression of lung injury or associated organ failures in a cohort of patients with acute lung injury.

Authors:  Daryl J Kor; Remzi Iscimen; Murat Yilmaz; Michael J Brown; Daniel R Brown; Ognjen Gajic
Journal:  Intensive Care Med       Date:  2009-01-31       Impact factor: 17.440

5.  Simvastatin inhibits leukocyte accumulation and vascular permeability in the retinas of rats with streptozotocin-induced diabetes.

Authors:  Shinsuke Miyahara; Junichi Kiryu; Kenji Yamashiro; Kazuaki Miyamoto; Fumitaka Hirose; Hiroshi Tamura; Hideto Katsuta; Kazuaki Nishijima; Akitaka Tsujikawa; Yoshihito Honda
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

Review 6.  Therapeutic and predictive targets of AKI.

Authors:  R Yalavarthy; C L Edelstein
Journal:  Clin Nephrol       Date:  2008-12       Impact factor: 0.975

Review 7.  Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review.

Authors:  Prabal K Chatterjee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-22       Impact factor: 3.000

8.  The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.

Authors:  V G Athyros; D P Mikhailidis; A A Papageorgiou; A N Symeonidis; A N Pehlivanidis; V I Bouloukos; M Elisaf
Journal:  J Clin Pathol       Date:  2004-07       Impact factor: 3.411

9.  Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects.

Authors:  H Yasuda; P S T Yuen; X Hu; H Zhou; R A Star
Journal:  Kidney Int       Date:  2006-05       Impact factor: 10.612

10.  Role of endogenous vitamin E in renal ischemic preconditioning process: differences between male and female rats.

Authors:  Simin Aryamanesh; Seyyed Meisam Ebrahimi; Nahid Abotaleb; Maliheh Nobakht; Parvaneh Rahimi-Moghaddam
Journal:  Iran Biomed J       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.